Furthermore, the authors demonstrated that c-Myc-driven myelomas are druggable by a potent new class of mTOR active site inhibitors that are able to block 4EBP1 phosphorylation, suggesting that targeting mTOR-dependent phosphorylation of 4EBP1 may represent a therapeutic strategy to target c-Myc in MM [72]. Here, MTOR is linked to plasma cell myeloma.